| Curex BCBS Illinois (HCSC) covers Wegovy only where your employer opts in
They complement lifestyle interventions such as diet and exercise in chronic disease management
Future Directions and Research Priorities Emerging Therapeutic Approaches Triple agonist retatrutide and combinations including cagrisema have progressed to phase 3 trials as obesity treatments with early data suggesting even greater weight loss than tirzepatide [83]
Use in Specific Populations Pediatric patients with type 1 diabetes treated with mealtime and postmeal Fiasp reported a higher rate of blood glucose confirmed hypoglycemic episodes compared to patients treated with NovoLog (insulin aspart) injection
We focus on behaviors, resistance training, protein targets, sleep , andwhen appropriate peptide support during taper to help maintain results
Authorship All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published
